Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called ...

Pfizer's stock has taken a tumble, but the story isn’t over—it's just pivoting to the next act. Once flying high on pandemic ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Fremanezumab (Ajovy) reduced depression symptoms and monthly migraine attacks in people with episodic or chronic migraine and ...

Arvinas announced that two drugs it was developing with pharmaceutical giant Pfizer were being dropped ... another New Haven-based biotech company, Biohaven. Biohaven officials said the company ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Since 2020, Pfizer has made significant investments in acquisitions, including Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics (GBT) for $5.4 billion ...